• Latest Posts

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Dutch FF Pharma has a Promising Immunotherapy to fight Crohn’s Disease

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease

Philogen targets Angiogenesis for cancer and Autoimmune Therapies

German Biotech raises extra €31M to get first-in-class Antibody through trials

Nanobody Phase II Results for Arthritis: Good but not good enough?

ADVERTISEMENT

Takeda snatches up Belgian Cell therapy for Crohn’s Disease

German Biotech launches Phase II in a hot Target for Inflammation

French T-cell Expert restarts trial for Crohn’s after Manufacturing Hiccup

Biotech of the Week: Avexxin, reducing inflammatory diseases from far up in Norway

Biotech of the Week: Covagen, binding proteins to antibodies for Immunotherapy

French Microbiome Therapy boosted by compound from major US Biotech

ADVERTISEMENT